Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers | Zendy

Yael Paran | Zendy; Esther Saiag | Zendy; Avishay Spitzer | Zendy; Yoel Angel | Zendy; Michal Yakubovsky | Zendy; Hagit Padova | Zendy; Ronen BenAmi | Zendy; Ilana Goldinger | Zendy; Ronni Gamzu | Zendy; Eli Sprecher | Zendy; David Zeltser | Zendy; Oryan Henig | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers

Author(s) -

Yael Paran,

Esther Saiag,

Avishay Spitzer,

Yoel Angel,

Michal Yakubovsky,

Hagit Padova,

Ronen BenAmi,

Ilana Goldinger,

Ronni Gamzu,

Eli Sprecher,

David Zeltser,

Oryan Henig

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab656

Subject(s) - medicine , booster (rocketry) , immunization , covid-19 , booster dose , titer , health care , virology , antibody , immunology , infectious disease (medical specialty) , outbreak , physics , disease , astronomy , economics , economic growth

This study demonstrated a favorable short-term safety profile after a third dose of the BNT162b2 vaccine among healthcare workers (HCWs). There were more frequent local reactions and less systemic reactions compared to the second dose. The HCWs who reported reactions had higher prebooster titer of anti-S1 antibodies compared to those who reported no reactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research